Skip to main content
SpringerLink
Log in

Optimum Use of Disease-Modifying and Immunosuppressive Antirheumatic Agents During Pregnancy and Lactation

  • Review Article
  • Treatment Review
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

An Erratum to this article was published on 01 August 1996

Summary

Women with rheumatic diseases frequently need treatment throughout pregnancy and lactation. Physicians must confront the dual challenge of monitoring the possible effects of the underlying maternal disease and the medications on both mother and child. It is essential that the maternal disease is well controlled before, during and after pregnancy to ensure the best possible outcome for the mother and child.

Glucocorticoids have been used extensively in pregnant patients with systemic lupus erythematosus and rheumatoid arthritis; there have been no reports of congenital malformations in the exposed infants. There is limited information on the safety of disease-modifying antirheumatic drugs, including hydroxychloroquine, cyclosporin, oral and parenteral gold and sulfasalazine, during pregnancy. However, penicillamine, another disease-modifying antirheumatic drug, is contra-indicated during pregnancy.

There is considerable experience with the use of azathioprine during pregnancy if the maternal condition requires a cytotoxic drug. There has been no increased risk of congenital malformations in the exposed infants. The other cytotoxic drugs frequently used in the treatment of rheumatic diseases, chlorambucil, cyclophosphamide and methotrexate, are contraindicated during pregnancy.

Glucocorticoids (such as prednisone and methylprednisolone) and hydroxychloroquine are considered to be safe during lactation. Oral and parenteral gold and sulfasalazine can be used with caution during lactation. Penicillamine, cyclosporin and all cytotoxic drugs are contraindicated during lactation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. Baltimore: Williams and Wilkins, 1989

    Google Scholar 

  2. Urowitz MB, Gladman DD, Farewell VT, et al. Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392–7

    Article  PubMed  CAS  Google Scholar 

  3. Cecere PA, Persellin RH. The interaction of pregnancy and the rheumatic diseases. Clin Rheumatol 1981; 7: 747–68

    Google Scholar 

  4. Needs C, Brooks P. Drugs, pregnancy, and rheumatoid arthritis. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby Year Book, 1994; 18: 4–6

    Google Scholar 

  5. Hazes JMW. Pregnancy and its effect on the risk of developing rheumatoid arthritis. Ann Rheum Dis 1991; 50: 71–4

    Article  PubMed  CAS  Google Scholar 

  6. Lockshin MD, Druzin ML. Rheumatic disease. In: Barron WM, Lindheimer MD, editors. Medical disorders during pregnancy. St Louis: Mosby Year Book, 1991; 366–99

    Google Scholar 

  7. Palit J, Clague RB. Wegener’s granulomatous presenting during first trimester of pregnancy. Br J Rheumatol 1990; 29: 389–90

    Article  PubMed  CAS  Google Scholar 

  8. Barron WB, Lindheimer MD, editors. Medical disorders during pregnancy. St Louis: Mosby Year Book, 1991

    Google Scholar 

  9. Corby DG. Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978; 62: 930–7

    PubMed  CAS  Google Scholar 

  10. Brooks PM, Needs CJ. The use of antirheumatic medication during pregnancy and in the Puerperium. Rheum Dis Clin North Am 1989; 15: 789–806

    PubMed  CAS  Google Scholar 

  11. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 1639–42

    Article  PubMed  CAS  Google Scholar 

  12. Barton JR, Sibal BM. Low-dose aspirin to improve perinatal outcome. Clin Obstet Gynecol 1991; 34: 251–61

    Article  PubMed  CAS  Google Scholar 

  13. Pritchard JA. Changes in blood volume during pregnancy and delivery. Anaesthesia 1965; 26: 293

    Google Scholar 

  14. Mendenhall HW. Serum protein concentrations in pregnancy. 1. Concentration in maternal serum. Am J Obstet Gynecol 1970; 106: 388

    PubMed  CAS  Google Scholar 

  15. Dettli L, Spring P. The modifying effect of physiologic variables and disease upon pharmacokinetics. In: Pharmacology and the future of man. Proceedings of the Fifth International Congress on Pharmacology; San Francisco, 1992: Basel, Karger: 3: 165–73

  16. The Nutrition Committee of the Canadian Pediatric Society and the Committee on Nutrition of the American Academy of Pediatrics. Breast feeding. Pediatrics 1978; 62: 591–601

    Google Scholar 

  17. Berlin CM. Pharmacological considerations of drug use in the lactating mother. Obstet Gynecol 1981; 58 Suppl.: 17–23

    CAS  Google Scholar 

  18. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 3: 206–21

    Article  Google Scholar 

  19. Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Balliere’s Clin Rheumatol 1990; 4: 467–89

    Article  CAS  Google Scholar 

  20. Fox RI, Kang H-I. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2 Suppl.: S9–S12

    Article  PubMed  CAS  Google Scholar 

  21. Fox R. Antimalarial drugs: mechanisms of action in autoimmune disease and prospects for drug development. Clin Immunother 1995; 4(3): 219–34

    Article  Google Scholar 

  22. Buchanan NMM, Toubi E, Khamashta MA, et al. The safety of hydroxychloroquine in lupus pregnancy: experience in 24 pregnancies. Br J Rheumatol 1995; 35 Suppl. 1: 14

    Google Scholar 

  23. Dencker L, Lindquist NJ, Ullberg S, et al. Distribution of an I-125 labelled chloroquin analogue in a pregnant macaca monkey. Toxicology 1975; 5: 255–64

    Article  PubMed  CAS  Google Scholar 

  24. Ullberg S, Lindquist NJ, Siostrand SE. Accumulation of chorioretinotoxic drugs in the foetal eye. Nature 1970; 227: 1257–8

    Article  PubMed  CAS  Google Scholar 

  25. Mgbodile MU. Effects of perinatal exposure of albino rats to chloroquin. Biol Neonate 1987; 51: 273–6

    Article  PubMed  CAS  Google Scholar 

  26. Campbell PM, Wilske K. In: Weaver AL, editor. Guidelines for reviewers of rheumatic disease care. 2nd ed. Atlanta: American College of Rheumatology, 1989

  27. O’Day R. SAARDS-I. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby Year Book, 1994; 12: 1–9

    Google Scholar 

  28. Akintonwa A. Placental and milk transfer of chloroquine in humans. Ther Drug Monit 1988; 10: 147–9

    Article  PubMed  CAS  Google Scholar 

  29. Neill WA, Panay GS, Duthie JJR, et al. Action of chloroquine phosphate in rheumatoid arthritis. II. chromosomal damaging effect. Ann Rheum Dis 1972; 32: 547–50

    Article  Google Scholar 

  30. Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. BMJ 1985; 290: 1466–7

    Article  PubMed  CAS  Google Scholar 

  31. Paufique L, Magnard P. Retinal degeneration in 2 children following preventive antimalarial treatment of mother during pregnancy. Bull Soc Ophthalmol Fr 1969; 69: 466–77

    CAS  Google Scholar 

  32. Parke AL. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988; 15: 607–10

    PubMed  CAS  Google Scholar 

  33. Hart CN, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964; 80: 407–12

    Article  CAS  Google Scholar 

  34. Ross JB, Garatsos S. Absence of chloroquine-induced ototoxicity in a fetus. Arch Dermatol 1974; 109: 573

    Article  PubMed  CAS  Google Scholar 

  35. MacKenzie AH. Antimalarial drugs for rheumatoid arthritis (oral gold symposium). Am J Med 1983; 75: 48–58

    Article  PubMed  CAS  Google Scholar 

  36. Roubenoff R, Hoyt I, Petri M, et al. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18: 88–110

    Article  PubMed  CAS  Google Scholar 

  37. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–4

    Article  Google Scholar 

  38. Merland R, Creste M. Study of the elimination and estimation of nivaquine in human milk. Med Trop 1951; 11: 793

    CAS  Google Scholar 

  39. Nation RL, Hackett LP, Dusci LG, et al. Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 1984; 17: 368–9

    Article  PubMed  CAS  Google Scholar 

  40. Ostensen M, Brown ND, Chiang PK, et al. Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol 1985; 28: 357

    Article  PubMed  CAS  Google Scholar 

  41. Anderson PO. Drugs and breast feeding. Drug Intell Clin Pharm 1977; 11: 210–1

    Google Scholar 

  42. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 1989; 84: 924–36

    Google Scholar 

  43. Tsokos GC. Immunomodulatory treatments in patients with rheumatic diseases: mechanism of action. Semin Arthritis Rheum 1987; 17: 24–38

    Article  PubMed  CAS  Google Scholar 

  44. Britton S, Palacios R. Cyclosporin A — usefulness, risks and mechanism of action. Immunol Rev 1982; 65: 5–22

    Article  PubMed  CAS  Google Scholar 

  45. Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporine-induced fetotoxicity in the rat. Transplantation 1985; 39: 9–12

    PubMed  CAS  Google Scholar 

  46. Brown PAJ, Gray ES, Whiting PH, et al. Effects of cyclosporin A on fetal development in the rat. Biol Neonate 1985; 48: 172–80

    Article  PubMed  CAS  Google Scholar 

  47. Tugwell P, Bombardier C, Geut M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051–5

    Article  PubMed  CAS  Google Scholar 

  48. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment refractory rheumatoid arthritis. Ann Intern Med 1988; 109: 863–9

    PubMed  CAS  Google Scholar 

  49. Kowal A, Carstens Jr JH, Schnitzer TJ. Cyclosporine in rheumatoid arthritis. In: Furst DE, Weinblatt ME, editors. Immunomodulators in the rheumatic diseases. New York: Marcel Dekker, 1990

    Google Scholar 

  50. Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37: 551–8

    Article  PubMed  CAS  Google Scholar 

  51. Lewis GJ, Larmont CAR, Lee HA, et al. Successful pregnancy in a renal transplant recipient taking cyclosporin A. BMJ 1983; 286: 603

    Article  PubMed  CAS  Google Scholar 

  52. Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis 1985; 5: 60–3

    PubMed  CAS  Google Scholar 

  53. Burrows DA, O’Neil TJ, Sorrells TL. Successful twin pregnancy after renal transplant maintained on cyclosporine A immunosuppression. Obstet Gynecol 1988; 72: 459–61

    PubMed  CAS  Google Scholar 

  54. Lowenstein BR, Vain NW, Perrone SV, et al. Successful pregnancy after and vaginal delivery after heart transplantation. Am J Obstet Gynecol 1988; 158: 589–90

    PubMed  CAS  Google Scholar 

  55. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992; 28: 148–52

    PubMed  CAS  Google Scholar 

  56. Cockburn I, Krupp P, Monka C. Present experience of Sandimmun in pregnancy. Transplant Proc 1989; 21: 3730–2

    PubMed  CAS  Google Scholar 

  57. Pujals JM, Figueras G, Puig JM, et al. Osseous malformation in baby born to woman on cyclosporin. Lancet 1989; 1: 667

    Article  PubMed  CAS  Google Scholar 

  58. Hussein MM, Mooij JMV, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993; 40: 160–3

    PubMed  CAS  Google Scholar 

  59. Calne RY, Brons IGM, Williams PF, et al. Successful pregnancy after paratropic segmental pancreas and kidney transplantation. BMJ 1988; 296: 1709

    Article  PubMed  CAS  Google Scholar 

  60. Baarsna R, Kamps WA. Immunological responses in an infant after cyclosporine A exposure during pregnancy. Eur J Pediatr 1993; 152: 476–7

    Article  Google Scholar 

  61. Product information. Sandimmune. Sandoz Pharmaceutical Corporation, 1991

  62. Joyce DA. D-Penicillamine. Clin Rheumatol 1990; 4: 553–74

    CAS  Google Scholar 

  63. Keen CL, Mark-Savage P, Lormerdal BO, et al. Teratogenic effects of d-penicillamine in rats: relation to copper deficiency. Drug Nutr Interact 1983; 2: 17–34

    PubMed  CAS  Google Scholar 

  64. Steffek AJ, Verussio AC, Watkins CA. Cleft palate in rodents after maternal treatment with lathyrogenic agents. Teratology 1972; 5: 33–8

    Article  PubMed  CAS  Google Scholar 

  65. Stivers FE, Steffek AJ, Yarington CT. Effect of lathyrogens on developing midfacial structures in the rat. J Surg Res 1971; 11: 415–20

    Article  PubMed  CAS  Google Scholar 

  66. Harpey JP, Jandon MC, Clavel JP, et al. Cutis laxa and low serum zinc after antenatal exposure to d-penicillamine in rats. Lancet 1983; 2: 858

    Article  PubMed  CAS  Google Scholar 

  67. Steen VD, Blair S, Medsger TAJ. The toxicity of d-penicillamine in systemic sclerosis. Ann Intern Med 1986; 104: 699–705

    PubMed  CAS  Google Scholar 

  68. Steen VD. When and how to use penicillamine for systemic sclerosis. J Musculoskeletal Med 1989; 4: 72–87

    Google Scholar 

  69. Lyle WH. Penicillamine in pregnancy. Lancet 1978; 1: 606–7

    Article  PubMed  CAS  Google Scholar 

  70. Mjolnerod OK, Rasmussen K, Dommerud SA, et al. Congenital connective-tissue defect probably due to d-penicillamine treatment in pregnancy. Lancet 1971; 1: 673–4

    Article  PubMed  CAS  Google Scholar 

  71. Solomon L, Abrams G, Dinner M, et al. Neonatal abnormalities associated with d-penicillamine treatment during pregnancy. N Engl J Med 1977; 296: 54–5

    Article  PubMed  CAS  Google Scholar 

  72. Gregory MC, Mansell MA. Pregnancy and cystinuria. Lancet 1983; 2: 1158–60

    Article  PubMed  CAS  Google Scholar 

  73. Paulus HE, Bulpitt KJ. Nonsteroidal antiinflammatory agents and corticosteroids. In: Schumacher HR, Klippel JH, Koopman WJ, editors. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation, 1993: 298–303

    Google Scholar 

  74. Walker B. Induction of cleft palate in rats with antiinflammatory drugs. Teratology 1971; 4: 39–42

    Article  PubMed  CAS  Google Scholar 

  75. Pinsky L, DiGeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science 1965; 147: 402–3

    Article  PubMed  CAS  Google Scholar 

  76. Walker BE. Induction of cleft palate in rabbits by several glucocorticoids. Proc Soc Exp Biol Med 1967; 125: 1281–4

    PubMed  CAS  Google Scholar 

  77. Reinisch JM, Simon NG. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202: 436–8

    Article  PubMed  CAS  Google Scholar 

  78. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994; 20: 87–118

    PubMed  CAS  Google Scholar 

  79. Blanford AT, Murphy BEP. In vitro metabolism of prednisone, dexamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127: 264–7

    PubMed  CAS  Google Scholar 

  80. Schardein JL. Chemically induced birth defects. New York: Marcel Dekker, 1985

    Google Scholar 

  81. Connolly ME. The pharmacologic management of systemic lupus erythematosus in pregnancy. Ann Intern Med 1981; 94: 671–2

    Google Scholar 

  82. Scott JR. Fetal growth retardation associated with maternal administration of immunosuppressives. Am J Obstet Gynecol 1977; 128: 668–76

    PubMed  CAS  Google Scholar 

  83. Kraus AM. Congenital cataract and maternal steroid injection. J Pediatr Ophthalmol Strabismus 1975; 12: 107–8

    Google Scholar 

  84. Cote CJ, Meuwissen HJ, Pickering RJ, et al. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 1974; 85: 324–8

    Article  PubMed  CAS  Google Scholar 

  85. Cederqvist LL, Merkatz IR, Litwin SD, et al. Fetal immunoglobulin synthesis following maternal immunosuppression. Am J Obstet Gynecol 1977; 129: 687–90

    PubMed  CAS  Google Scholar 

  86. Ramsey-Goldman R. Pregnancy in systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14: 169–85

    PubMed  CAS  Google Scholar 

  87. Grigor RR, Shervington PC, Hughes GRV, et al. Outcome of pregnancy in systemic lupus erythematosus. Proc Soc Exp Biol Med 1977; 70: 99–100

    CAS  Google Scholar 

  88. Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. J Pediatr 1985; 106: 1008–111

    Article  PubMed  CAS  Google Scholar 

  89. Szabo KT, Difebb ME, Phelan DG. The effect of gold containing compounds on pregnant rabbits and their fetuses. Vet Pathol 1978; 15: 95–8

    Google Scholar 

  90. Anonymous. Drugs for rheumatoid arthritis. Med Lett Drugs Ther 1994; 36: 101–6

  91. Richards AJ. Transfer of gold from mother to foetus. Lancet 1977; 1: 99

    Article  PubMed  CAS  Google Scholar 

  92. Rocker I, Hendeson MJH. Transfer of gold from mother to foetus. Lancet 1976; 2: 1246

    Article  PubMed  CAS  Google Scholar 

  93. Miyamoto T, Miyaji S, Horiuchi T, et al. Gold therapy in bronchial asthma: special emphasis upon blood levels of gold and its teratogenicity. Nippon Naika Gakkai Zasshi 1974; 63: 190–7

    Article  Google Scholar 

  94. Tozman ECS, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol Adverse Drug Exper 1987; 2: 177–89

    Article  CAS  Google Scholar 

  95. Blau SP. Metabolism of gold during lactation. Arthritis Rheum 1973; 16: 777–8

    Article  PubMed  CAS  Google Scholar 

  96. Xiong JM, Liang B, Mo YQ, et al. Teratologic studies of methyl 5-aminosalicylate and salicylazopyridine. Acta Pharmacol Sin 1992; 13: 265–7

    CAS  Google Scholar 

  97. Folb PI, Graham Dukes MN, editors. Drug safety in pregnancy. Amsterdam: Elsevier, 1990

    Google Scholar 

  98. Jarnerot G, Into-Malmberg MB, Esbjorner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16: 693–7

    Article  PubMed  CAS  Google Scholar 

  99. Mogadam M, Dobbins WOIII, Korelitz BI, et al. Pregnancy in IBD: effect of sulphasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80: 72–6

    PubMed  CAS  Google Scholar 

  100. Craxi A, Pagliarello F. Possible embryotoxicity of sulfasalazine [letter]. Arch Intern Med 1980; 140: 1674

    Article  PubMed  CAS  Google Scholar 

  101. Hoo JJ, Hadro TA, von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 1988; 318: 1128

    PubMed  CAS  Google Scholar 

  102. Newman NM, Correy JF. Possible teratogenicity of sulphasalazine. Med J Aust 1983; 1: 528–9

    PubMed  CAS  Google Scholar 

  103. Levi S, Liberman M, Levi AJ, et al. Reversible congenital neutropenia associated with maternal sulphasalazine therapy [letter]. Eur J Pediatr 1988; 148: 174–5

    Article  PubMed  CAS  Google Scholar 

  104. Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea — a possible complication of sulphasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986; 5: 316–7

    PubMed  CAS  Google Scholar 

  105. McKendry RJR. Purine analogs. In: Dixon JS, Furst DE, editors. Second line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1991

    Google Scholar 

  106. Clements PJ. Cytotoxic immunosuppressive drugs. In: Paulus HE, Furst DE, Dromgooles H, editors. Drugs for rheumatic disease. New York: Marcel Dekker, 1987: 135–6

    Google Scholar 

  107. Furst DE, Clements PJ. SAARDs-II. In: Klippel JH, Dieppe PE, editors. Rheumatology. London: Mosby Year Book, 1994; 13: 1–7

    Google Scholar 

  108. Githens JH, Rosencrantz JG, Tunnock SM, et al. Teratogenic effects of azathioprine (Imuran). J Pediatr 1965; 66: 962–3

    Article  Google Scholar 

  109. Fujii TM, Kowa Y. Teratogenesis of azathioprine (Imuran) in mice and rats. Oyo Yakuri 1968; 2: 401

    Google Scholar 

  110. Tuchmann-Duplessis H, Mercier-Parot L. Production in rabbits of malformations of the extremities by administration of azathioprine and 6-mercaptopurine. C R Seances Soc Biol Fil 1966; 160: 501–6

    PubMed  CAS  Google Scholar 

  111. Davison JM, Dellagrammatikas H, Parkin JM, et al. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985; 92: 233–9

    Article  PubMed  CAS  Google Scholar 

  112. Rudolph JE, Schweizer RT, Bartkus SA. Pregnancy in renal transplant patients. Transplantation 1979; 27: 26–9

    Article  PubMed  CAS  Google Scholar 

  113. The Registration Committee of the European Dialysis and Transplant Association. Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol 1980; 87: 839–45

    Article  Google Scholar 

  114. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528–33

    Article  PubMed  CAS  Google Scholar 

  115. Leb DE, Weisskopf B, Kanovitz BS. Chromosome aberrations in the child of a kidney transplant recipient. Arch Intern Med 1971; 128: 441–4

    Article  PubMed  CAS  Google Scholar 

  116. Marushak A, Weber T, Bock J, et al. Pregnancy following kidney transplantation. Acta Obstet Gynecol Scand 1986; 65: 557–9

    Article  PubMed  CAS  Google Scholar 

  117. Davison JM, Lindheimer MD. Pregnancy in renal transplant recipients. J Reprod Med 1982; 27: 613–21

    PubMed  CAS  Google Scholar 

  118. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol 1981; 58: 247–50

    PubMed  CAS  Google Scholar 

  119. Nishimura H, Tanimura T. Clinical aspects of the teratogenicity of drugs. New York: American Elsevier, 1976

    Google Scholar 

  120. Burleson RL, Sunderji SG, Aubry RH, et al. Renal allotransplantation during pregnancy: successful outcome for mother, child, and kidney. Transplantation 1983; 36: 334

    Article  PubMed  CAS  Google Scholar 

  121. Ogburn PLJ, Kitzmiller JL, Hare JW, et al. Pregnancy following renal transplantation in class T diabetes mellitus. JAMA 1986; 255: 911–5

    Article  PubMed  Google Scholar 

  122. De Witte DB, Buick MK, Cyran SE, et al. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984; 105: 625–8

    Article  Google Scholar 

  123. Haagsma EB, Visser GH, Klompmaker IJ, et al. Successful pregnancy after orthotropic transplantation. Obstet Gynecol 1989; 74: 442–3

    PubMed  CAS  Google Scholar 

  124. Coulam CB, Moyer TP, Jiang NS, et al. Breast-feeding after renal transplantation. Transplant Proc 1982; 14: 605–9

    PubMed  CAS  Google Scholar 

  125. Cannon GW, Ward JR. Cytotoxic drugs and sulfasalazine. In: McCarty D, editor. Arthritis and allied conditions. 2nd ed. Philadelphia: Lea and Febiger, 1989

    Google Scholar 

  126. Klinenberg JR, Reichman R, Clements PJ. Investigational therapy for rheumatoid arthritis. In: Progress in clinical immunology, vol. 1. New York: Grune and Stratton, 1984

    Google Scholar 

  127. Lawler SD, Lele KP. Chromosomal damage induced by chlorambucil and chronic lymphocytic leukemia. Scand J Haematol 1972; 17: 197–204

    Google Scholar 

  128. Westin J. Chromosome abnormalities after chlorambucil therapy of polycythemia vera. Scand J Haematol 1976; 17: 197–204

    Article  PubMed  CAS  Google Scholar 

  129. Clements PJ. Alkylating agents. In: Dixon JS, Furst DE, editors. Second line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1991

    Google Scholar 

  130. Kahn MF, Arlet J, Bloch-Michel H, et al. Leucemies aigues apres traitement par agents cytotoxiques en rheumatologies: 19 observations chez 2006 patients. Nouv Presse Med 1979; 8: 1393–7

    PubMed  CAS  Google Scholar 

  131. Monie IW. Chlorambucil-induced abnormalities of urogenital system of rat fetuses. Anat Rec 1961; 139: 145

    Article  PubMed  CAS  Google Scholar 

  132. Takacs SE, Warkany J. Chromosome changes in embryos treated with various teratogens. J Embryol Exp Morphol 1967; 18: 215–26

    PubMed  Google Scholar 

  133. Brummett ES, Johnson EM. Morphological alterations in the developing fetal rat limb due to maternal injection of chlorambucil. Teratology 1979; 20: 279–88

    Article  PubMed  CAS  Google Scholar 

  134. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood 1981; 58: 849–51

    PubMed  CAS  Google Scholar 

  135. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin releasing hormone. Lancet 1981; 1: 1132–4

    Article  PubMed  CAS  Google Scholar 

  136. Ataya KM, McKanna JA, Weintraub AM, et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Treat Rev 1985; 45: 3651–6

    CAS  Google Scholar 

  137. Nseyo UO, Huben RP, Klioze SS, et al. Protection of germinal epithelium with luteinizing hormone-releasing hormone analogue. J Urol 1985; 34: 187–90

    Google Scholar 

  138. Sokal JE, Lessmann EM. Effects of cancer chemotherapeutic agents on the human fetus. JAMA 1960; 172: 1765–71

    Article  CAS  Google Scholar 

  139. Shotton D, Monie IW. Possible teratogenic effect of chlorambucil on a human fetus. JAMA 1963; 186: 74–5

    Article  PubMed  CAS  Google Scholar 

  140. Steege JF, Caldwell DS. Renal agenesis after first trimester exposure to chlorambucil. South Med J 1980; 73: 1414–5

    Article  PubMed  CAS  Google Scholar 

  141. Thompson J, Conklin KA. Anesthetic management of a pregnant patient with scleroderma. Anaesthesiology 1983; 59: 69–71

    Article  CAS  Google Scholar 

  142. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–9

    Article  PubMed  Google Scholar 

  143. Hackenberger I, Kreybig T. Vergleichende teratologische Untersuchungen bei der maus und der ratte. Arzneimittel Forschung 1965; 15: 1456–60

    PubMed  CAS  Google Scholar 

  144. Chaube S, Kury G, Murphy ML, et al. Teratogenic effects of cyclophosphamide in the rat. Cancer Chemother Biol Response Modif 1967; 51: 363–76

    Google Scholar 

  145. Gerlinger P, Clavert J. Anomalies observees chez des lapins issus de meres traitees au cyclophosphamide. C R Seances Soc Biol Fil 1965; 159: 1462–6

    CAS  Google Scholar 

  146. Fritz H, Hess R. Effects of cyclophosphamide on embryonic development in the rabbit. Agents Actions 1971; 2: 83–6

    Article  PubMed  CAS  Google Scholar 

  147. Wilk A, McClure HM, Horigan EA, et al. Induction of craniofacial malformations in the rhesus monkey with cyclophosphamide. Teratology 1978; 17: 24A

    Google Scholar 

  148. Koyama H, Wada T, Nishizawa Y. Induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403–9

    Article  PubMed  CAS  Google Scholar 

  149. Boumpas DT, Austin HA III, Vaughn EM, et al. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366–9

    PubMed  CAS  Google Scholar 

  150. Nicholson HO. Cytotoxic drugs in pregnancy: review of reported cases. J Obstet Gynaecol 1968; 75: 307–12

    Article  CAS  Google Scholar 

  151. Kirshon B, Wasserstrum N, Willis R, et al. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72: 462–4

    PubMed  CAS  Google Scholar 

  152. Pizzuto J, Aviles A, Noriega L, et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 1980; 64: 679–83

    PubMed  CAS  Google Scholar 

  153. Greenberg LH, Tanaka KR. Congenital anomalies probably induced by cyclophosphamide. JAMA 1964; 188: 423–6

    Article  PubMed  CAS  Google Scholar 

  154. Toledo TM, Harper RC, Moser RH. Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 1971; 74: 87–91

    PubMed  CAS  Google Scholar 

  155. Coates A. Cyclophosphamide in pregnancy. Aust J Obstet Gynaecol 1970; 10: 33–4

    Article  CAS  Google Scholar 

  156. Murray CL, Reichert JA, Anderson J, et al. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. JAMA 1984; 252: 2607–8

    Article  PubMed  CAS  Google Scholar 

  157. Sweet DL, Kinzie J. Consequences of radiotherapy and antineoplastic therapy for the fetus. J Reprod Med 1976; 17: 241–6

    PubMed  Google Scholar 

  158. Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet 1971; 1: 912

    Article  PubMed  CAS  Google Scholar 

  159. Mullarkey MF, Blumenstein BA, Andrade P, et al. Methotrexate in the treatment of corticosteroid-dependent asthma. N Engl J Med 1988; 318: 603–7

    Article  PubMed  CAS  Google Scholar 

  160. Songstridey N, Furst DE. Methotrexate — the rapidly acting drug. Clin Rheumatol 1990; 4: 575–94

    Google Scholar 

  161. Rothenberg RJ, Graziano FM, Grandone JT, et al. The use of methotrexate in steroid-resistant SLE. Arthritis Rheum 1988; 31: 612–5

    Article  PubMed  CAS  Google Scholar 

  162. DePaola DP, Mandella RD. Folate deficiency and in vitro palatogenesis II: effects of methotrexate on rabbit palate fusion, folate pools, and dihydrofolate reductase activity. J Craniofac Genet Dev Biol 1984; 4: 321–7

    PubMed  CAS  Google Scholar 

  163. Zamenhof S. Differential effects of antifolate on the development of brain parts in chick embryos. Growth 1985; 49: 28–33

    PubMed  CAS  Google Scholar 

  164. Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974; 9: 159–64

    Article  PubMed  CAS  Google Scholar 

  165. Schmid BP. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate, or cyclosporine A. Toxicology 1984; 31: 9–21

    Article  PubMed  CAS  Google Scholar 

  166. Adams CE, Hay M, Lutwak-Mann C, et al. The actions of various agents on the rabbit embryo. J Embryol Exper Morphol 1961; 9: 468–91

    CAS  Google Scholar 

  167. Wilson JG, Scott WJ, Ritter EJ, et al. Comparative distribution and embryotoxicity of methotrexate in pregnant rats and Rhesus monkeys. Teratology 1979; 19: 71–80

    Article  PubMed  Google Scholar 

  168. Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole — a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358–60

    Article  PubMed  CAS  Google Scholar 

  169. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989; 150: 613–9

    PubMed  CAS  Google Scholar 

  170. Milunsky A, Jick H, Jick SS. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262: 2847–52

    Article  PubMed  CAS  Google Scholar 

  171. Kremer JM, Alarcon GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28

    Article  PubMed  CAS  Google Scholar 

  172. Chotiner HC. Nonsurgical management of ectopic pregnancy associated with severe hyperstimulation syndrome. Obstet Gynecol 1985; 66: 740–3

    PubMed  CAS  Google Scholar 

  173. Oyer R. Treatment of cervical pregnancy with methotrexate. Obstet Gynecol 1988; 71: 469–71

    PubMed  CAS  Google Scholar 

  174. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Baltimore: Williams and Wilkins, 1986

    Google Scholar 

  175. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589–92

    Article  PubMed  CAS  Google Scholar 

  176. Waiden PAM, Bagshawe KD. Pregnancies after chemotherapy for gestational trophoblastic tumours. Lancet 1979; 2: 1241

    Google Scholar 

  177. Turchi JJ, Villasis C. Anthracyclines in the treatment of malignancy in pregnancy. Cancer 1988; 61: 435–40

    Article  PubMed  CAS  Google Scholar 

  178. Barnes AB, Link DA. Childhood dermatomyositis and pregnancy. Am J Obstet Gynecol 1983; 146: 335–6

    PubMed  CAS  Google Scholar 

  179. Sivanesaratnam V, Sen DK. Normal pregnancy after successful treatment of choriocarcinoma with cerebral metastases: a case report. J Reprod Med 1988; 33: 402–3

    PubMed  CAS  Google Scholar 

  180. Schleuning M, Clemm C. Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N Engl J Med 1987; 317: 1666–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Arthritis and Connective Tissue Diseases, Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA

    Rosalind Ramsey-Goldman & Ellen Schilling

Authors
  1. Rosalind Ramsey-Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259510.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramsey-Goldman, R., Schilling, E. Optimum Use of Disease-Modifying and Immunosuppressive Antirheumatic Agents During Pregnancy and Lactation. Clin Immunother 5, 40–58 (1996). https://doi.org/10.1007/BF03259314

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259314

Keywords

Search

Navigation